AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15236989
Drug: Platelet-activating factor
RxNorm normalized name: Platelet-activating factor acetyltransferase
DrugBank: Platelet Activating Factor (DB02261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-activating factor (PAF) treatment during IUI
Trial: 9717591
Drug: i.t. sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.t. sufentanil plus 2.5 mg plain bupivacaine (Group B)
Trial: 10641571
Drug: GM-CSF injected
RxNorm normalized name: axatilimab-csfr Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF injected intradermally into a single dermal metastasis and into a normal skin site for 10 consecutive days at one of four dose levels (10, 20, 40, or 80 microg/injection)
Trial: 6582073
Drug: Isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin administered 1 hour before a meal
Trial: 6582073
Drug: Isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin administered concomitantly with a meal
Trial: 6582073
Drug: Isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin administered 1 hour after a meal
Trial: 6582073
Drug: Isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin administered during a complete fast
Trial: 6582073
Drug: Isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin administered with food
Trial: 23210735
Drug: Peri-incisional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-incisional triamcinolone acetonide (PITMC) injection
Trial: 19889502
Drug: MMD procedural
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MMD procedural preparation (MMD-PP)
Trial: 11886474
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg (Group A, n = 46)
Trial: 11886474
Drug: Bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate 125 mg plus tetracycline 500 mg and furazolidone 200 mg (Group B, n = 46)
Trial: 11886474
Drug: No resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No resistance to clarithromycin or amoxicillin
Trial: 8344690
Drug: n-IL-2 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-IL-2 therapy
Trial: 3755051
Drug: Brl 20627
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brl 20627 (10 mg)
Trial: 24885187
Drug: trastuzumab-containing neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab-containing neoadjuvant therapy
Trial: 18776819
Drug: Glycerol (oral)
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol (oral)
Trial: 18776819
Drug: Glycerol (oral)
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol (oral) + Dexamethasone (intravenous)
Trial: 18776819
Drug: Dexamethasone (intravenous)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (intravenous)
Trial: 12906021
Drug: Oral Valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Valganciclovir
Trial: 12906021
Drug: Intravenous Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Ganciclovir
Trial: 10589650
Drug: Ulinastatin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (5000 U/kg) administered 2 min before vecuronium (0.1 mg/kg)
Trial: 8886680
Drug: Hartmanns solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmanns solution
Trial: 1281726
Drug: Terazosin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (10 mg/d)
Trial: 6374804
Drug: 750-ml collapsible
RxNorm normalized name: BREATHERITE SPACER COLLAPSIBLE BR200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750-ml collapsible spacer
Trial: 30672174
Drug: Acupuncture A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture A group (Tongdu Tiaoshen acupuncture, daily treatment)
Trial: 30672174
Drug: Acupuncture B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture B group (Tongdu Tiaoshen acupuncture, treatment every other day)
Trial: 30672174
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (nimodipine tablets, 30 mg three times daily)
Trial: 12393368
Drug: Remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3 micro g kg(‐1) h(‐1)
Trial: 12393368
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg kg(‐1) h(‐1)
Trial: 10457148
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid (5 mg daily for six weeks)
Trial: 2120769
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg naproxen daily for a week
Trial: 2120769
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg naproxen daily for a week
Trial: 2120769
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 750 mg and 1000 mg naproxen
Trial: 911007
Drug: Daily drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily drug reminder chart with concurrent pharmacist supervision
Trial: 28784312
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and fluorouracil (CF); two 3-weekly cycles of cisplatin [80 mg/m2 intravenously on day 1] and fluorouracil [1 g/m2 per day intravenously on days 1-4]
Trial: 28784312
Drug: Epirubicin, cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin, cisplatin, and capecitabine (ECX); four 3-weekly cycles of epirubicin [50 mg/m2], cisplatin [60 mg/m2], and capecitabine [1250 mg/m2 daily throughout the four cycles]
Trial: 20705516
Drug: Artesunate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (100 mg) with sulfalene (250 mg) plus pyrimethamine (12.5 mg) for 3 days
Trial: 20705516
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg per day)
Trial: 15842977
Drug: JTT-705 600
RxNorm normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTT-705 600 mg
Trial: 12895217
Drug: Dimethylpolysiloxane, sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylpolysiloxane, sodium bicarbonate and pronase (treatment C)
Trial: 12895217
Drug: Dimethylpolysiloxane alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylpolysiloxane alone (treatment A)
Trial: 12895217
Drug: Dimethylpolysiloxane plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylpolysiloxane plus sodium bicarbonate (treatment B)
Trial: 10526276
Drug: Concurrent thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thoracic irradiation (50 grays in 20 fractions, initiated after the second cycle of chemotherapy)
Trial: 10526276
Drug: Alternating thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating thoracic irradiation (20 grays in 8 fractions followed by 15 grays in 6 fractions, scheduled between chemotherapy cycles)
Trial: 6121577
Drug: Diacetolol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacetolol 200 mg/day
Trial: 6121577
Drug: Diacetolol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacetolol 400 mg/day
Trial: 6121577
Drug: Diacetolol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacetolol 800 mg/day
Trial: 19077889
Drug: Intraoperative surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative surfactant treatment (bovine surfactant at a dose of 20 mg phospholipids/kg)
Trial: 19077889
Drug: Intraoperative surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative surfactant treatment
Trial: 8892713
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Trial: 8892713
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus MPA, 2.5 mg/d daily
Trial: 8892713
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus micronized progesterone (MP), 200 mg/d for 12 d/mo
Trial: 6681024
Drug: Minoxidil (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil (5-40 mg/day)
Trial: 6681024
Drug: Hydralazine (25-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (25-200 mg/day)
Trial: 30623821
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy (FFT-A)
Trial: 28269582
Drug: Progressive abduction
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive abduction loading therapy
Trial: 21042013
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (increasing dose until serum total CO(2) ≥ 24 mM)
Trial: 21042013
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same medications, no sodium bicarbonate)
Trial: 16697413
Drug: Sertraline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline with transdermal estrogen (ET)
Trial: 16697413
Drug: Sertraline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline with placebo
Trial: 10235440
Drug: 5.1 g
RxNorm normalized name: POVIDONE-IODINE 5.1 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.1 g n-3 FA daily for 6 months
Trial: 10235440
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g n-3 FA daily for another 4 weeks (after initial treatment)
Trial: 7022037
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and glucagon combination
Trial: 31389157
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily oral modified release morphine
Trial: 26991683
Drug: Nurses who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurses who reported being 'somewhat comfortable' referring patients to CAM therapies
Trial: 26991683
Drug: Nurses who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurses who reported being 'very comfortable' referring patients to CAM therapies
Trial: 26991683
Drug: Nurses with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses with formal CAM education referring patients to CAM therapies
Trial: 22844698
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (0.34 g/kg)
Trial: 22844698
Drug: Medium sodium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium sodium diet (1.34 g/kg)
Trial: 22844698
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (2.82 g/kg)
Trial: 19602953
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (combination of one of four hypnotic drugs supplemented by one of four opioids)
Trial: 15269071
Drug: No influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No influenza vaccine (Control)
Trial: 12477513
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (group B; n = 16) for 4 months
Trial: 12477513
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs for 2 months, followed by carnitines for 2 months (group C; n = 26)
Trial: 12477513
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory treatment given concomitantly with carnitines (group D; n = 26) for 4 months
Trial: 9822455
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of the ACE inhibitor enalaprilat
Trial: 2696937
Drug: proxibarbal (Ipronal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: proxibarbal (Ipronal "Polfa") 50 mg tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Trial: 2696937
Drug: placebo tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Trial: 22741442
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg bid
Trial: 798626
Drug: Tamoxifen 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 15 mg/m2 bid
Trial: 18990678
Drug: Budesonide (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (low-dose inhaled corticosteroid)
Trial: 14986244
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral clinafloxacin treatment for native valve infection
Trial: 14986244
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral clinafloxacin treatment for prosthetic valve endocarditis (PVE)
Trial: 11380230
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and radiotherapy (CRT)
Trial: 11380230
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and radiotherapy (CRT) after radical resection
Trial: 9222074
Drug: Alatrofloxacin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin 30 mg
Trial: 9222074
Drug: Alatrofloxacin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin 100 mg
Trial: 9222074
Drug: Alatrofloxacin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin 200 mg
Trial: 9222074
Drug: Alatrofloxacin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin 300 mg
Trial: 9222074
Drug: Alatrofloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin (all doses)
Trial: 8107184
Drug: Isosorbide-5-mononitrate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (60 mg)
Trial: 3663551
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (150 mg) alone
Trial: 3663551
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate in combination with human menopausal gonadotrophins (hMG)
Trial: 3663551
Drug: Clomiphene in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene in combination with hMG
Trial: 26695486
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg testosterone undecanoate (Nebido(®))
Trial: 26695486
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate, and 100 mg testosterone decanoate (Sustanon(®))
Trial: 21674594
Drug: Experimental OAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental OAB drug
Trial: 11069725
Drug: Full irrigation
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full irrigation with 3000 ml of saline
Trial: 11069725
Drug: Minimal irrigation
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal irrigation with 250 ml saline
Trial: 9312318
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution 0.9%
Trial: 8467542
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 2 ml bolus/10 min lockout interval
Trial: 8467542
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 3 ml bolus/15 min lockout interval
Trial: 8467542
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 4 ml bolus/20 min lockout interval
Trial: 8467542
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 6 ml bolus/30 min lockout interval
Trial: 8467542
Drug: Group E:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E: 8 ml/hr continuous infusion
Trial: 3468737
Drug: EMG biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG biofeedback treatment (8 sessions, twice a week for 4 weeks)
Trial: 15854633
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral
Trial: 10752774
Drug: Short-term glucose
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term glucose infusion of 25 g in 30 min
Trial: 10752774
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose infusion of 10 g/h
Trial: 8638536
Drug: Neoadjuvant intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant intraarterial infusion chemotherapy with 25 mg/m2 of cisplatin and 15 mg/m2 of bleomycin via each internal iliac artery.
Trial: 8638536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving radiation therapy (external irradiation and intracavitary irradiation).
Trial: 6533162
Drug: Intracarotid urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracarotid urokinase injections
Trial: 22659373
Drug: Simvastatin alone
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin alone (40 mg/day)
Trial: 22659373
Drug: Ezetimibe/Simvastatin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin combined therapy (10/20 or 10/40 mg/day)
Trial: 20481650
Drug: Vicriviroc 75
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 75 mg alone
Trial: 20481650
Drug: Vicriviroc 15
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 15 mg after 4 days of ritonavir 100 mg once daily
Trial: 20481650
Drug: Ritonavir treatment
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir treatment
Trial: 18588757
Drug: Nasal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation (daily until 6 months after RT)
Trial: 12431355
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (Edmonston-Zagreb, Leningrad-Zagreb, RA 27/3 strains)
Trial: 12431355
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (Moraten, Jeryl Lynn, Wistar 27/3 strains)
Trial: 12431355
Drug: Vaccine C
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine C (Schwartz, Urabe AM-9, Wistar 27/3 strains)
Trial: 10507269
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (0.25 mg, 0.50 mg, or 1.0 mg)
Trial: 10507269
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (0.50 mg and 1.0 mg)
Trial: 31918984
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval exercise (HIIE) with 10% evening basal insulin reduction
Trial: 31918984
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval exercise (HIIE) with 20% evening basal insulin reduction